Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy

CD19-targeted chimeric antigen receptor (CAR) T-cell becomes a breakthrough therapy providing excellent remission rates and durable disease control for patients with relapsed/refractory (R/R) hematologic malignancies. However, CAR T-cells have several potential side effects including cytokine releas...

Descripción completa

Detalles Bibliográficos
Autores principales: Wudhikarn, Kitsada, Perales, Miguel-Angel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285870/
https://www.ncbi.nlm.nih.gov/pubmed/35840746
http://dx.doi.org/10.1038/s41409-022-01756-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9285870/
https://www.ncbi.nlm.nih.gov/pubmed/35840746
http://dx.doi.org/10.1038/s41409-022-01756-w

Ejemplares similares